ZHONGSHAN, China - s4story -- On March 28, 2025, Transtek Medical(stock code: [300562.SZ]) announced its 2024 annual results, reporting solid growth across key financial metrics. For the reporting period, Transtek achieved revenue of RMB 984 million, representing an 11.28% year-on-year increase. Net profit attributable to shareholders rose sharply by 78.55% to RMB 61.36 million. The company's overall gross margin improved to 35.07%, up 4.13 percentage points from the previous year.

Throughout 2024, Transtek continued to advance its strategic positioning as a provider of medical-grade remote health monitoring devices and services. The company expanded its chronic disease management product portfolio, including smart blood pressure monitors, medical-grade ECG vests, blood glucose meters, body composition scales, OTC hearing aids, and smart wearables. These devices cover key health parameters such as blood pressure, blood glucose, body composition, PPG, ECG, physical activity, sleep, atrial fibrillation, and arrhythmias, and have obtained medical certifications across China, the U.S., Europe, and South Korea.

More on S For Story

• NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
• Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
• Do You Know Why Nobody Sits Like the French?
• ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa

In product development, Transtek made strategic progress in smart blood glucose monitoring, with products registered with the U.S. FDA and listed by SIGIS. Its subsidiary focusing on remote ECG services secured approval for the iSENSE 12-lead smart ECG vest as a Class II medical device.

Leveraging technological innovation, Transtek launched an AI-driven cardiovascular health model, integrating smart monitoring devices with AI healthcare services to deliver inclusive digital chronic disease management.

Looking forward, Transtek will continue to enrich its medical-grade product lineup, strengthen its technological leadership, and deepen its presence in global markets. The company remains committed to driving high-quality growth and expanding its role in the digital health ecosystem.

Founded in 2000, Transtek is committed to multiple health fields such as remote health and chronic disease management, providing customers with medical-grade "RPM devices" and "cloud services". Transtek also provides one-stop connectivity technology, device management, and fulfillment services for Remote Patient Monitoring (RPM) providers. Transtek has established a co-branded solution named TeleRPM since 2019, it stands for Quality & Value which is the best of Transtek. TeleRPM is an integrated solution which includes cellular blood pressure monitor, cellular weight scale, cellular blood glucose meter and all-round BLE package with AnyHub solution. Also, TeleRPM is open and scalable, and Transtek will leverage their expertise to help customers realize greater value, potential and outcomes.

More on S For Story

• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success